Selective small-molecule inhibitors of protein kinases can serve as powerful tools to
elucidate biological function. Efforts to develop potential drug candidates have yielded a …

Cancer development requires that tumour cells attain several capabilities, including
increased replicative potentials, anchorage and growth-factor independency, evasion of …

Many human malignancies are associated with deregulated activation of protein or lipid
kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein …

Cancer is one of the most dreadful and highly prevailing life-threatening ailments of the
modern age. Despite a great advancement in the health sector, still it is the leading cause of …

Kinase inhibitors are the largest class of new cancer drugs. However, it is already apparent
that most tumours can escape from the inhibition of any single kinase. If it is necessary to …

Kinases, which number> 500 in humans, are a class of enzymes that participate in an array
of important functions within normal cellular physiology and during various pathological …

An increasing number of kinase inhibitor candidates are entering clinical development,
representing an important change in the pharmaceutical industry; notably, the development …

Human protein kinases (PKs) represent the third largest enzyme class and are responsible
for modifying an estimated one-third of the human proteome. 1 These enzymes catalyze the …

There are over 500 human kinases ranging from very well-studied to almost completely
ignored. Kinases are tractable and implicated in many diseases, making them ideal targets …

Great successes have been achieved in developing small-molecule kinase inhibitors as
anticancer therapeutic agents. However, kinase deregulation plays essential roles not only …